Holen Sie sich die Stockscreener-App
56.68
0.30%
-0.17
Handel nachbörslich:
56.00
-0.68
-1.20%
Schlusskurs vom Vortag:
$56.85
Offen:
$56.73
24-Stunden-Volumen:
1.70M
Relative Volume:
0.60
Marktkapitalisierung:
$10.89B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
21.07
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
-0.16%
1M Leistung:
-5.45%
6M Leistung:
-2.51%
1J Leistung:
-10.39%
1-Tages-Spanne:
$56.01
$57.33
1-Wochen-Bereich:
$55.50
$58.33
52-Wochen-Spanne:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
56.68 | 10.92B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.91 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.13 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.75 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
349.58 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) - Finviz
Double-digit Revenue Growth Till 2030 Drives BioMarin’s (BMRN) Bullish Thesis - Insider Monkey
Double-digit Revenue Growth Till 2030 Drives BioMarin's (BMRN) Bullish Thesis - Finviz
BioMarin to offer $850 million in notes to fund Amicus acquisition By Investing.com - Investing.com Nigeria
BioMarin Plans to Offer $850 Million in Senior Unsecured Notes - Intellectia AI
BioMarin to offer $850 million in notes to fund Amicus acquisition - Investing.com
BioMarin lines up $2B loan, $800M facility for Amicus deal - Stock Titan
10 Cheap Stocks with Huge Upside Potential - Insider Monkey
BioMarin Plans $850M Senior Unsecured Notes Offering - Intellectia AI
Y Intercept Hong Kong Ltd Sells 51,159 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Sector Gamma AS Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Rakuten Investment Management Inc. Acquires New Shares in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Is Quietly Exploding — Is BMRN the Biotech Stock You’re Sleeping On? - AD HOC NEWS
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case - Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
BioMarin vets form Mendra to ‘modernize’ rare disease drug development - BioPharma Dive
Ex-BioMarin execs launch Mendra with $82M to 'modernise' rare disease R&D - FirstWord Pharma
Liquidity Mapping Around (BMRN) Price Events - Stock Traders Daily
BioMarin Pharmaceutical (NASDAQ:BMRN) Raised to Buy at Canaccord Genuity Group - MarketBeat
Campbell & CO Investment Adviser LLC Trims Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biotech Stocks Facing FDA Decision In February 2026 - RTTNews
BioMarin stock rating upgraded by Canaccord Genuity on Amicus acquisition By Investing.com - Investing.com Nigeria
BioMarin stock rating upgraded by Canaccord Genuity on Amicus acquisition - Investing.com UK
BioMarin names new chief accounting officer - MSN
Aug Volume: Is BioMarin Pharmaceutical Inc stock risky to hold nowDividend Hike & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Has $24.48 Million Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin (BMRN) Elevating Digital Strategy To Sharpen Its Innovation And Efficiency Edge? - Sahm
Korea’s Ildong promotes Chae Joon Lee to co-CEO - BioCentury
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical - The Globe and Mail
BioMarin’s PALace Study: Long-Term Safety Check on Palynziq and What It Means for Investors - TipRanks
11 potential new genetic-disease medicines as BioMarin maps $4B push - Stock Titan
BioMarin drops development of liver, lung disease asset - MSN
A Look At BioMarin Pharmaceutical (BMRN) Valuation After New Chief Digital And Information Officer Appointment - Sahm
Humana Partners With Atlas to Enhance Cancer Care for Seniors - TradingView — Track All Markets
4 Value Stocks to Buy As Wall Street Weighs Trump Policies - The Globe and Mail
BioMarin names Arpit Davé as Chief Digital and Information Officer - The American Bazaar
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com
BMRN or TARS: Which Is the Better Value Stock Right Now? - Yahoo Finance
Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now? - Yahoo Finance
BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference - MarketBeat
BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down - marketscreener.com
BioMarin appoints Arpit Davé as chief digital and information officer By Investing.com - Investing.com Nigeria
Lobbying Update: $30,000 of BIOMARIN PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
BioMarin appoints Arpit Davé as chief digital and information officer - Investing.com
Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FYSEC filing - marketscreener.com
BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer - marketscreener.com
BMRN: Strong growth, pipeline progress, and Amicus integration position for sustained double-digit CAGR - TradingView
BioMarin Appoints Arpit Davé Chief Digital and Information Officer - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.49%
4.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):